Literature DB >> 18332869

Retinoblastoma protein modulates gankyrin-MDM2 in regulation of p53 stability and chemosensitivity in cancer cells.

W Qiu1, J Wu, E M Walsh, Y Zhang, C-Y Chen, J Fujita, Z-X J Xiao.   

Abstract

MDM2 is a key ubiquitin E3 ligase for p53 and its activity is critically regulated by a set of modulators, including ARF, p300, YY1 and recently by gankyrin, an oncoprotein frequently overexpressed in human heptocellular carcinomas. We have previously shown that MDM2 binds to and promotes retinoblastoma protein (Rb) degradation. Here we show that Rb inhibits MDM2 E3 ligase activity resulting in stabilization of p53. In addition, we demonstrated that Rb inhibits MDM2-mediated p53 ubiquitination in a gankyrin-dependent manner and the Rb-gankyrin interaction is critical for Rb-induced p53 stabilization. Furthermore, acute ablation of Rb facilitates gankyrin-mediated p53 destabilization, and desensitizes cancer cells for chemotherapy-induced apoptosis. These results indicate that Rb antagonizes gankyrin to inhibit MDM2-mediate p53 ubiquitination in cancer cells and suggest that the status of both p53 and Rb is important for efficacy of cancer chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18332869     DOI: 10.1038/onc.2008.43

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

Review 1.  Gankyrin as a potential therapeutic target for cancer.

Authors:  Chongchong Wang; Li Cheng
Journal:  Invest New Drugs       Date:  2017-05-19       Impact factor: 3.850

Review 2.  Inhibition of apoptosis by oncogenic hepatitis B virus X protein: Implications for the treatment of hepatocellular carcinoma.

Authors:  Chuck C K Chao
Journal:  World J Hepatol       Date:  2016-09-08

Review 3.  Scratching the Surface: Resurfacing Proteins to Endow New Properties and Function.

Authors:  Alex M Chapman; Brian R McNaughton
Journal:  Cell Chem Biol       Date:  2016-05-19       Impact factor: 8.116

4.  Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K/AKT/HIF-1α/cyclin D1 pathway.

Authors:  J Chen; M Bai; C Ning; B Xie; J Zhang; H Liao; J Xiong; X Tao; D Yan; X Xi; X Chen; Y Yu; R C Bast; Z Zhang; Y Feng; W Zheng
Journal:  Oncogene       Date:  2015-09-14       Impact factor: 9.867

Review 5.  Tumour suppressor genes in chemotherapeutic drug response.

Authors:  Dulcie Lai; Stacy Visser-Grieve; Xiaolong Yang
Journal:  Biosci Rep       Date:  2012-08       Impact factor: 3.840

6.  The Complex Relationship between Liver Cancer and the Cell Cycle: A Story of Multiple Regulations.

Authors:  Xavier Bisteau; Matias J Caldez; Philipp Kaldis
Journal:  Cancers (Basel)       Date:  2014-01-13       Impact factor: 6.639

7.  Gankyrin is a predictive and oncogenic factor in well-differentiated and dedifferentiated liposarcoma.

Authors:  Ju-Ae Hwang; Heung-Mo Yang; Doo-Pyo Hong; Sung-Yeon Joo; Yoon-La Choi; Joo-Hung Park; Alexander J Lazar; Raphael E Pollock; Dina Lev; Sung Joo Kim
Journal:  Oncotarget       Date:  2014-10-15

8.  A miR-199a/miR-214 self-regulatory network via PSMD10, TP53 and DNMT1 in testicular germ cell tumor.

Authors:  Bi-Feng Chen; Yick-Keung Suen; Shen Gu; Lu Li; Wai-Yee Chan
Journal:  Sci Rep       Date:  2014-09-18       Impact factor: 4.379

9.  Testis specific Y-like 5: gene expression, methylation and implications for drug sensitivity in prostate carcinoma.

Authors:  Senthil R Kumar; Jeffrey N Bryan; Magda Esebua; James Amos-Landgraf; Tanner J May
Journal:  BMC Cancer       Date:  2017-02-24       Impact factor: 4.430

10.  Discovery of a small-molecule binder of the oncoprotein gankyrin that modulates gankyrin activity in the cell.

Authors:  Anasuya Chattopadhyay; Cornelius J O'Connor; Fengzhi Zhang; Celine Galvagnion; Warren R J D Galloway; Yaw Sing Tan; Jamie E Stokes; Taufiq Rahman; Chandra Verma; David R Spring; Laura S Itzhaki
Journal:  Sci Rep       Date:  2016-04-05       Impact factor: 4.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.